Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Commentary|Articles|September 11, 2025
FLAURA-2 and HARMONi Trial Readouts Reinforce Importance of ‘Divide and Conquer’ Approach to Lung Cancer Care at WCLC 2025
Author(s)Courtney Flaherty
Fact checked by: Ashley Chan
Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.
Advertisement
Advertisement
The
Related to this article
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Advertisement
Advertisement